WaveMan
WaveMan · Company
PROK · Prokidney Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

PROK Prokidney (PROK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001850270
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
47
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced

What the filings say about PROK

Insiders, 180 days
-$1.1M net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.1M
2 notices

Prokidney insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PROKIDNEY CORP. insiders sold a net $1.1M of stock across 74 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Pereira Brian JG
Director
SELL
2026-08-20 SEC
222,948
$316.6K
-15.5%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 19, 2026.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pereira Brian JG sold about $316.6K of PROK on Aug 20, 2026; 47 funds added in the latest 13F quarter.
Pereira Brian JG
Director
SELL
2026-08-20 SEC
27,052
$38.4K
-15.5%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 19, 2026.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pereira Brian JG sold about $38.4K of PROK on Aug 20, 2026; 47 funds added in the latest 13F quarter.
Pereira Brian JG
Director
SELL
2026-08-20 SECtraded 2026-08-19
222,949
$321.2K
-15.5%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 18, 2026.
  • The trade is 100.0% of the 222,948 shares held after it.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pereira Brian JG sold about $321.2K of PROK on Aug 19, 2026; 47 funds added in the latest 13F quarter.
Pereira Brian JG
Director
SELL
2026-08-20 SECtraded 2026-08-19
27,051
$39.0K
-15.5%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 18, 2026.
  • The trade is 100.0% of the 27,052 shares held after it.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pereira Brian JG sold about $39.0K of PROK on Aug 19, 2026; 47 funds added in the latest 13F quarter.
Pereira Brian JG
Director
SELL
2026-08-20 SECtraded 2026-08-18
229,338
$314.5K
-15.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 13, 2025.
  • The trade is 51.4% of the 445,897 shares held after it.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pereira Brian JG sold about $314.5K of PROK on Aug 18, 2026; 47 funds added in the latest 13F quarter.
74 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 69 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.1M over 180 days
-$1.1M over 90 days
below 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
47 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
+1075.0% year over year
more than 96% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
12.9% of the float short (float per yahoo 2026-10-26) · 11.0 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PROK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-57.4%12M
-58%-39%-19%+1%2025-102025-122026-022026-042026-062026-082026-10 2025-11-13 · Pereira Brian JG sold $1.1M2025-11-12 · Pereira Brian JG sold $618.6K2026-08-19 · Pereira Brian JG sold $321.2K2026-08-20 · Pereira Brian JG sold $316.6K2026-08-18 · Pereira Brian JG sold $314.5K2025-11-13 · Pereira Brian JG sold $128.8K2025-11-12 · Pereira Brian JG sold $75.1K2026-08-19 · Pereira Brian JG sold $39.0K2026-08-20 · Pereira Brian JG sold $38.4K2026-08-18 · Pereira Brian JG sold $38.2K2026-08-18 · Brian Pereira filed to sell $114.0K2026-08-18 · Brian Pereira filed to sell $945.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PROK: institutional holders (13F)

13F holdings, latest reported quarter
MONTANOVA CAPITAL, LLC
12,341,266 sh
$25.2M
MORGAN STANLEY
9,854,178 sh
$20.1M
BlackRock, Inc.
5,197,227 sh
$10.6M
GEODE CAPITAL MANAGEMENT, LLC
2,390,147 sh
$4.9M
Bleichroeder LP
2,000,000 sh
$4.1M

Congress trades in PROK

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PROK planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Brian Pereira
Filed 2026-08-18
$114.0K
Brian Pereira
Filed 2026-08-18
$945.3K

PROK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$291.9K position · as of 2026-07-31
0.6%
Inception Portfolio
$596.6K position · as of 2026-06-30
0.2%
Discovery Portfolio
$1.7M position · as of 2026-06-30
0.2%
Global Insight Portfolio
$113.6K position · as of 2026-06-30
0.2%
Morgan Stanley Insight Fund
$2.3M position · as of 2026-06-30
0.2%
Discovery Portfolio
$348.7K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
3
Phase 2
0 active
2
Phase 3
1 active
2
Not applicable
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.1M sold by insiders over 180 days, 47 funds added last quarter, $1.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PROK financials

Revenue growth
+1075.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$818.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$159.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-27.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-62.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$893.0K$76.0K$0$0
Operating income-$165.0M-$183.7M-$151.5M-$153.0M
Net income-$69.0M-$61.2M-$35.5M-$148.1M
EPS (diluted)n/an/an/a-0.23
Operating cash flow-$120.1M-$126.4M-$90.1M-$77.1M
Cash$108.5M$99.1M$60.6M$490.3M
Buybacks$0$0$9.5M$0
SEC XBRL, fiscal years, as known on 2026-10-28

PROK Stock Sonar score 5/7 axes

Find similar shapesCompare

PROK ranks highest on growth (96th percentile) and risk and compliance (55th), and lowest on insider conviction (18th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
52
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-27.1% · 63 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-62.2% · 41 pct, sector of 576
Growth
96
Inputs
  • Revenue growth, YoY+1075% · 96 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.1M · 35 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
46
Inputs
  • Funds adding, latest quarter47 · 46 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
  • Short interest, % of float+12.9% · 31 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.9% · 79 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PROK filings, in plain words

Are Prokidney insiders buying or selling PROK?

In the 180 days to 2026-10-28, Prokidney insiders were net sellers, a net $1.1M across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of PROK?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.1M of stock; the latest, by Brian Pereira, was filed 2026-08-18.

Read the full summary

In the 180 days to 2026-10-28, Prokidney insiders were net sellers of PROK, a net $1.1M across purchases and sales reported on Form 4 by 1 seller. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies